Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer

Prostate Cancer and Prostatic Diseases volume 13, pages 162–167 (2010)Cite this article

Subjects

Abstract

The aim of this study was to determine the treatment patterns and resource utilization of various prostate cancer treatments, and quantify the economic and clinical impact of each. In a retrospective analysis of medical and pharmacy claims between 2000 and 2005, using the PharMetrics database, male patients aged ≥40 years with prostate cancer diagnosis were identified. The costs of medical and prostate cancer-related expenditures for the treatment options were determined for three periods: from diagnosis to first treatment, during and after treatment. A total of 9035 patients were included. The mean age of patients diagnosed with prostate cancer was 61.4 years. Patients aged 50–59 years represented the highest proportion at 51%. The majority received some form of treatment. Watchful waiting (WW) was the primary means of management for 30%. The average 2-year cost for WW was $24 809 and for active treatment was $59 286. Surgery was the most common treatment among younger men. Non-cancer-related costs were similar among those receiving treatment or WW, but prostate cancer costs were over five times greater in the treated patients. With or without treatment, prostate cancer is a significant clinical and economic burden to society. New strategies for treatment or cancer prevention could play a role in reducing this burden.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. American Cancer Society. Cancer Facts & Figures 2007. American Cancer Society: Atlanta, 2007.

  2. American Cancer Society (ACS). Cancer Facts & Figures: 2008. Available at http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf; accessed March 2008.

  3. National Cancer Institute (NCI). Cancer Trends Progress Report—2007 Update. Available at http://progressreport.cancer.gov; accessed March 2008.

  4. Chodak G . Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 2006; 8: S3–S8.

    PubMed  PubMed Central  Google Scholar 

  5. Johansson JE, Holmber L, Johansson S, Bergström R, Adami HO . Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 1997; 277: 467–471.

    Article  CAS  Google Scholar 

  6. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22: 3524–3530.

    Article  Google Scholar 

  7. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L . The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004; 171: 2250–2254.

    Article  Google Scholar 

  8. International Classification of Diseases. Ninth Revision, Clinical Modification (ICD-9-CM). Centers for Disease Control and Prevention: Hyattsville, MD, 1979.

  9. Mag Mutual. Physician's Fee and Coding Guide 2008. MAG Mutual Healthcare Solutions, Inc: Atlanta, GA, USA

  10. Yan Y, Carvalhal GF, Catalona WJ, Young JD . Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 1999; 88: 1122–1130.

    Article  Google Scholar 

  11. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–1984.

    Article  CAS  Google Scholar 

  12. National Comprehensive Cancer Network and American Cancer Society, Prostate Cancer. Treatment Guidelines for Patients, Version VI, October 2007.

  13. Anastasiadis AG, Salomon L, Katz R, Hoznek A, Chopin D, Abbou CC . Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology 2003; 62: 292–297.

    Article  Google Scholar 

  14. Cohn JH, El-Galley R . Radical prostatectomy in a community practice. J Urol 2002; 167: 224–228.

    Article  Google Scholar 

  15. Cooperberg MR, Moul JW, Carroll PR . The changing face of prostate cancer. J Clin Oncol 2005; 23: 8146–8151; review.

    Article  Google Scholar 

  16. Albertsen PC, Hanley JA, Fine J . 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095–2101.

    Article  CAS  Google Scholar 

  17. Wallace, M . Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 2003; 30: 3003–3309.

    Article  Google Scholar 

  18. Bailey DE, Wallace M . Critical review: is watchful waiting a viable management option for older men with prostate cancer? Am J Men's Health 2007; 1: 18–28.

    Article  Google Scholar 

  19. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39–51.

    Article  CAS  Google Scholar 

  20. Musquera M, Fleshner NE, Finelli A, Zlotta AR . The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008; 8: 1073–1079.

    Article  CAS  Google Scholar 

  21. Andriole GL . Headline results of the REDUCE trial: the effect of dutasteride on prostate cancer risk reduction. Presented at: American Urological Association 2009 Annual Meeting; April 25–30, 2009; Chicago, IL. http://webcasts.prous.com/AUA2009/html/1-en/template.aspx?section=20&idl=7632&eid=212; accessed July 24, 2009.

  22. Brown ML, Riley GF, Schussler N, Etzioni R . Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002; 40 (Suppl 8): IV104–117.

    Google Scholar 

  23. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.

    Article  CAS  Google Scholar 

  24. Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK . A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 2007; 89: 207–211.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Funding for the research described in this paper, as well as for preparation of the paper, was provided by GlaxoSmithKline to Xcenda, LLC.

Author information

Authors and Affiliations

  1. Department of Urologic Oncology, University of Colorado, Denver, CO, USA

    E D Crawford

  2. GlaxoSmithKline, Research Triangle Park, NC, USA

    L Black

  3. Xcenda, LLC, Palm Harbor, FL, USA

    M Eaddy & E J Kruep

Authors
  1. E D Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Black
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Eaddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E J Kruep
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Eaddy.

Ethics declarations

Competing interests

Drs Eaddy and Kruep are employed at Xcenda. Dr Crawford received an honorarium from Xcenda for his professional services relevant to this study and the paper. Dr Black is employed at GlaxoSmithKline.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crawford, E., Black, L., Eaddy, M. et al. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 13, 162–167 (2010). https://doi.org/10.1038/pcan.2009.63

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.63

Keywords

This article is cited by

Search

Advanced search

Quick links